Overview
Rolandic epilepsy-speech dyspraxia syndrome (also known as RE-SD syndrome, or epilepsy with centrotemporal spikes and speech dyspraxia) is a rare genetic epilepsy syndrome that affects the brain, specifically the rolandic (centrotemporal) region responsible for motor control of the face, mouth, and speech. It is characterized by the combination of benign rolandic epilepsy (childhood epilepsy with centrotemporal spikes) and oromotor dysfunction manifesting as speech dyspraxia — a condition in which individuals have difficulty planning and coordinating the movements needed for speech. The syndrome has been linked to mutations in the GRIN2A gene, which encodes a subunit of the NMDA glutamate receptor, a critical component of excitatory neurotransmission in the brain. Key clinical features include focal seizures that typically occur during sleep, often involving twitching of the face or mouth, drooling, and difficulty speaking during the episode. Between seizures, affected individuals demonstrate oral and speech motor planning difficulties (dyspraxia), which can range from mild articulation problems to severe speech impairment. Some patients may also experience cognitive difficulties, including problems with reading and language development. The seizures associated with this syndrome typically begin in childhood and may remit by adolescence, similar to classic benign rolandic epilepsy, though the speech dyspraxia may persist. Treatment is primarily symptomatic. Antiepileptic medications such as carbamazepine, levetiracetam, or sulthiame may be used to control seizures. Speech and language therapy is an important component of management to address the oromotor dyspraxia. The prognosis for seizure control is generally favorable, as seizures often resolve with age, but the degree of speech and language recovery varies among individuals. Genetic counseling is recommended for affected families given the hereditary nature of the condition.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Rolandic epilepsy-speech dyspraxia syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Rolandic epilepsy-speech dyspraxia syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Rolandic epilepsy-speech dyspraxia syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Rolandic epilepsy-speech dyspraxia syndrome.
Community
No community posts yet. Be the first to share your experience with Rolandic epilepsy-speech dyspraxia syndrome.
Start the conversation →Latest news about Rolandic epilepsy-speech dyspraxia syndrome
No recent news articles for Rolandic epilepsy-speech dyspraxia syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Rolandic epilepsy-speech dyspraxia syndrome
What is Rolandic epilepsy-speech dyspraxia syndrome?
Rolandic epilepsy-speech dyspraxia syndrome (also known as RE-SD syndrome, or epilepsy with centrotemporal spikes and speech dyspraxia) is a rare genetic epilepsy syndrome that affects the brain, specifically the rolandic (centrotemporal) region responsible for motor control of the face, mouth, and speech. It is characterized by the combination of benign rolandic epilepsy (childhood epilepsy with centrotemporal spikes) and oromotor dysfunction manifesting as speech dyspraxia — a condition in which individuals have difficulty planning and coordinating the movements needed for speech. The syndro
How is Rolandic epilepsy-speech dyspraxia syndrome inherited?
Rolandic epilepsy-speech dyspraxia syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Rolandic epilepsy-speech dyspraxia syndrome typically begin?
Typical onset of Rolandic epilepsy-speech dyspraxia syndrome is childhood. Age of onset can vary across affected individuals.